Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice

Monte, Massimo Dal; Casini, G.; Marca, Giancarlo la; Isacchi, Benedetta; Filippi, Luca; Bagnoli, Paola

doi:10.1016/j.exer.2013.03.013

Cited by 45 publications

(54 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is probably due to the high partition coefficient of propranolol; in fact, it is well known that the corneal epithelium does not offer resistance to the penetration of the very lipophilic β-blockers, such as propranolol (26). After the test with one drop at 1, 0.5, or 0.1%, the concentrations measured did not always change proportionally to the variation of the solution's concentration suggesting a nonlinear kinetics, as previously reported in mice (14). However, the 0.1% concentration was chosen for chronic administration because the corresponding plasma concentration showed a safer pharmacokinetic profile.…”

Section: Discussionsupporting

confidence: 50%

“…Unfortunately, no data were reported about propranolol delivery to the posterior segment of the eye (13). In a recent study, we have demonstrated in mice with OIR that propranolol dissolved in commercially available eye drops (2% concentration) efficiently reaches the retina and promotes the recovery of OIR, suggesting that trans-corneal application of propranolol can lead to adequate penetration of the drug in the posterior segment of the eye (14). However, no specific pharmacokinetic study has been performed at present.…”

Section: Discussionmentioning

confidence: 99%

“…mice with OIR reducing their retinal neovascularization (14) has been recently demonstrated, thus opening the perspective for a possible treatment of ROP with propranolol eye drops.…”

Section: Articlesmentioning

confidence: 99%

“…In studies in which propranolol-based eye drops were used in humans and mice (14,25), the safety profile was not investigated. With this study we were able to demonstrate that propranolol-based ocular drops at 0.1% concentration are safe and do not alter ocular structures.…”

Section: Articlesmentioning

confidence: 99%

See 3 more Smart Citations

Pharmacokinetics and local safety profile of propranolol eye drops in rabbits

et al. 2014

Self Cite

View full text Add to dashboard Cite

Background: Oral propranolol, a nonselective β-blocker, is able to reduce the progression of retinopathy of prematurity in newborns, but it appeared unsafe. This study aimed to find, in rabbits, a propranolol eye drop concentration able to induce lower plasma but higher retinal concentrations than those obtained after oral administration. Methods: Male New Zealand white rabbits were treated with oral propranolol (0.25 mg/kg/6 h) for 5 d, and propranolol concentrations were measured after 1, 2, 3, and 6 h in plasma, aqueous humor, vitreous humor, and retina. These concentrations were compared with those obtained after the administration of one drop of 25 μl of propranolol 0.1% prepared in saline, applied every 6 h to both eyes for 5 d. A Draize eye test and histological analyses were performed to assess eye drop tolerability. results: The administration of eye drops produced retinal concentrations similar to, but plasma concentrations significantly lower than, those measured after oral administration. The local tolerability profile was excellent. conclusion: Propranolol eye drops are able to ensure high retinal and low plasma concentrations of propranolol, and this finding opens the perspective of possible topical treatment with propranolol in newborns with retinopathy of prematurity.

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Discussionmentioning

confidence: 99%

“…mice with OIR reducing their retinal neovascularization (14) has been recently demonstrated, thus opening the perspective for a possible treatment of ROP with propranolol eye drops.…”

Section: Articlesmentioning

confidence: 99%

Section: Articlesmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacokinetics and local safety profile of propranolol eye drops in rabbits

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…[11] Recent studies have shown propranolol can reduce VEGF production in oxygen-induced retinopathy. [11][12][13] Currently, there is no evidence of propranolol effect on CNV except only one study in 2014 that reported a non-significant effect. [10] ORIGINAL ARTICLE Therefore, the present study was aimed to investigate the anti-angiogenic effects of topical administration propranolol in experimentally-induced CNV in a rabbit model.…”

Section: Introductionmentioning

confidence: 99%

Untitled

Kasiri

2017

AJP

View full text Add to dashboard Cite

Objective: To evaluate the effects of topical propranolol for treatment of the corneal neovascularization (CNV) in a rabbit model of corneal injury. Methods: The CNV model was induced by 3 sutures of the cornea in 20 rabbits (20 corneas). 2 weeks after CNV, all sutures were removed then rabbits were divided randomly into two groups: Groups 1 received topical propranolol 10 mg/mL and Group 2 received only topical normal saline drops as control group, in the right eyes three times a day for 2 weeks. Photographs of (CNV) were obtained before drug administration and at 1 and 2 weeks after therapy. The images were analyzed using NIH Image J1.49c software. Results:The mean percentage of CNV area estimated as 100% before treatment. At the 1 week after treatment, the mean percentage of NV area in propranolol and saline group were 78.01 ± 4.16 and 93.33 ± 4.57, respectively. Moreover, at the 2 weeks after treatment were 65.72 ± 4.15 and 84.96 ± 5.21, respectively. After 1 and 2 weeks treatment, the NV area in propranolol group was regressed more than saline group significantly (P < 0.0001). Conclusion: Topical administration of propranolol reduces CNV in the short-term, but the efficacy of long-term treatment needs more investigations.

show abstract